Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

Provided By PR Newswire

Last update: Feb 23, 2022

NEW YORK, Feb. 23, 2022 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced plans to develop Bryostatin-1 for the treatment of multiple sclerosis ("MS"), a third indication for the drug candidate. The Company will collaborate with the Cleveland Clinic through a new consulting agreement.